159 related articles for article (PubMed ID: 17579260)
1. Plasma levels of unactivated thrombin activatable fibrinolysis inhibitor (TAFI) are down-regulated in young adult women: analysis of a normal Japanese population.
Akatsu H; Ishiguro M; Ogawa N; Kanesaka T; Okada N; Yamamoto T; Campbell W; Okada H
Microbiol Immunol; 2007; 51(5):507-17. PubMed ID: 17579260
[TBL] [Abstract][Full Text] [Related]
2. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact.
Frère C; Morange PE; Saut N; Tregouet DA; Grosley M; Beltran J; Juhan-Vague I; Alessi MC
Thromb Haemost; 2005 Aug; 94(2):373-9. PubMed ID: 16113828
[TBL] [Abstract][Full Text] [Related]
3. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD).
Verdú J; Marco P; Benlloch S; Sanchez J; Lucas J
Thromb Haemost; 2006 Mar; 95(3):585-6. PubMed ID: 16525595
[No Abstract] [Full Text] [Related]
4. TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction.
Akatsu H; Yamagata H; Chen Y; Miki T; Kamino K; Takeda M; Campbell W; Kondo I; Kosaka K; Yamamoto T; Okada H
Br J Haematol; 2004 Nov; 127(4):440-7. PubMed ID: 15521922
[TBL] [Abstract][Full Text] [Related]
5. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Antovic JP; Blombäck M
Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
[TBL] [Abstract][Full Text] [Related]
6. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays.
Guimarães AH; van Tilburg NH; Vos HL; Bertina RM; Rijken DC
Br J Haematol; 2004 Mar; 124(5):659-65. PubMed ID: 14871254
[TBL] [Abstract][Full Text] [Related]
7. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
Kamal HM; Ahmed AS; Fawzy MS; Mohamed FA; Elbaz AA
Acta Cardiol; 2011 Aug; 66(4):483-8. PubMed ID: 21894805
[TBL] [Abstract][Full Text] [Related]
8. Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity.
Hamdy M; Shaheen IA; Khallaf M; Selim YMM
Pediatr Blood Cancer; 2024 Jun; 71(6):e30959. PubMed ID: 38520679
[TBL] [Abstract][Full Text] [Related]
9. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis].
González FJ; Caturla JM; Fernández M; Carrasco R; Marco P; Sánchez J; Benlloch S
Med Intensiva; 2010 Nov; 34(8):513-22. PubMed ID: 20627371
[TBL] [Abstract][Full Text] [Related]
10. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
Zorio E; Castelló R; Falcó C; España F; Osa A; Almenar L; Aznar J; Estellés A
Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
[TBL] [Abstract][Full Text] [Related]
11. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.
Schneider M; Boffa M; Stewart R; Rahman M; Koschinsky M; Nesheim M
J Biol Chem; 2002 Jan; 277(2):1021-30. PubMed ID: 11684677
[TBL] [Abstract][Full Text] [Related]
12. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
Juhan-Vague I; Morange PE; Aubert H; Henry M; Aillaud MF; Alessi MC; Samnegård A; Hawe E; Yudkin J; Margaglione M; Di Minno G; Hamsten A; Humphries SE;
Arterioscler Thromb Vasc Biol; 2002 May; 22(5):867-73. PubMed ID: 12006404
[TBL] [Abstract][Full Text] [Related]
13. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.
Bridge KI; Bollen L; Zhong J; Hesketh M; Macrae FL; Johnson A; Philippou H; Scott DJ; Gils A; Ariёns RAS
J Thromb Haemost; 2017 Nov; 15(11):2218-2225. PubMed ID: 28834317
[TBL] [Abstract][Full Text] [Related]
14. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study.
de Bruijne EL; Gils A; Guimarães AH; Dippel DW; Deckers JW; van den Meiracker AH; Poldermans D; Rijken DC; Declerck PJ; de Maat MP; Leebeek FW
J Thromb Haemost; 2009 Jun; 7(6):919-27. PubMed ID: 19323787
[TBL] [Abstract][Full Text] [Related]
15. A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor.
Stanne TM; Olsson M; Lorentzen E; Pedersen A; Gummesson A; Gils A; Jood K; Engström G; Melander O; Declerck PJ; Jern C
Thromb Haemost; 2018 Feb; 118(2):298-308. PubMed ID: 29378355
[TBL] [Abstract][Full Text] [Related]
16. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets.
Mosnier LO; Buijtenhuijs P; Marx PF; Meijers JC; Bouma BN
Blood; 2003 Jun; 101(12):4844-6. PubMed ID: 12595308
[TBL] [Abstract][Full Text] [Related]
17. Preferential detection of pro-carboxypeptidase R by enzyme-linked immunosorbent assay.
Tani S; Akatsu H; Ishikawa Y; Okada N; Okada H
Microbiol Immunol; 2003; 47(4):295-300. PubMed ID: 12801067
[TBL] [Abstract][Full Text] [Related]
18. On-demand but not prophylactic treatment with FVIII concentrate increase thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients.
Mikovic D; Woodhams BJ; Holmström M; Elezovic I; Antovic A; Mobarrez F; Elfvinge P; Antovic JP
Int J Lab Hematol; 2012 Feb; 34(1):35-40. PubMed ID: 21707936
[TBL] [Abstract][Full Text] [Related]
19. Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension.
Yaoita N; Satoh K; Satoh T; Sugimura K; Tatebe S; Yamamoto S; Aoki T; Miura M; Miyata S; Kawamura T; Horiuchi H; Fukumoto Y; Shimokawa H
Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1293-301. PubMed ID: 27102961
[TBL] [Abstract][Full Text] [Related]
20. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
Chengwei X; Xiaoli M; Yuan Z; Li P; Shengjiang W; Chao Y; Yunshan W
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
